

November 5, 2024
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Corporate Vice President and Global CMO

TOKYO, November 5, 2024 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, hereinafter “SymBio”) today announced that effective November 4, 2024, Dr. Jay Marshall Feingold, MD, PhD, (hereinafter “Dr. Feingold”) will be joining SymBio as Corporate Vice President and concurrently, as Global Chief Medical Officer (“CMO”). Dr. Feingold will also serve as Senior Vice President of SymBio Pharma USA, Inc. (established in May 2016, a wholly-owned U.S. subsidiary of SymBio Pharmaceuticals Limited).

Moving forward, as our company expands its business into hematological malignancies and solid tumors in addition to post-transplant viral infections, Dr. Feingold, who has a career as a transplant physician and extensive development experience in major blood cancers and solid tumors, will lead our global operations to further strengthen our global development organizational structure. By accelerating the development and commercialization of BCV in Europe, the United States, and Japan, we will steadily grow as a global specialty pharmaceutical company.

Statement from Dr. Jay Feingold: “I am excited to work with the SymBio team to further develop BCV in multiple therapies for patients seeking new treatments for devastating diseases that currently have no treatment options. We will strive to achieve results as quickly as possible while focused on quality and patient quality of life.

Statement from Fuminori Yoshida, President and CEO of SymBio: “I am very pleased to welcome Dr. Feingold, who has outstanding knowledge of the global development business, a proven track record of developing numerous new drugs, and is also an experienced transplant physician, to our management team. We will further strengthen our development infrastructure to achieve a global specialty pharmaceutical company.”

[Contact]

Investor Relations, Administrative Division
Tel: +81(0)3 5472 1125

